Takeda’s Post

Thailand has the second-largest pharmaceutical market in Southeast Asia after Indonesia. According to the market research company BMI, sales are set to rise from 3.8 billion US dollars (US$) in 2022 to 9.4 billion in 2032, driven by an ageing population, higher income and the expansion of healthcare. But why foreign pharmaceutical manufacturers hardly produce or be involved in research and development in Thailand? Read more from an article written by Mr. Thomas Hundt, Director of Thailand, Cambodia, Myanmar, and Laos at Germany Trade & Invest (GTAI), here>> https://lnkd.in/gZNYjP3n #GTCCUPDATEMagazine #PharmaceuticalIndustry #Pharma #Trends #healthcare #GTCC #AHKThailand #PartnerForSuccess #PartnerInThailand #PartnerWorldwide

Here is a good article in Chain Drug Review.

On #BiotechHangout today Daphne Zohar, Brad Loncar, John Maraganore, Josh Schimmer, Bruce Booth & Yaron Werber, M.D., MBA cover $ABBV / $IMGN $10B acquisition, FDA’s CAR-T safety concerns, data setbacks & wins ($ROIV, $ARGX, $XENE, & $IVMT), $REGN & $SNY seek to expand Dupixent approval to COPD, $SWTX approval, plus JAMA Internal Medicine paper calls to eliminate orphan drug exemptions, $SLRN & $BIVI point to CRO errors in trial failures, X Prize $101M prize in aging + financings/biotech sentiment Listen here: https://lnkd.in/ejhkm9BY

It's interesting that The Lancet addresses housing as a key social determinant of health. We briefly touched on this in our 2019 report on collaboration in the pharmaceutical industry, where we highlighted this issue (page 19 of the attached). As always, I'm keen to hear innovative strategies industry might adopt to combat preventable health issues proactively. https://lnkd.in/esDR2cED

🌟 Breaking News in Medical Science! 🌟 Exciting developments from Denali Therapeutics. as they unveil groundbreaking results in the fight against mucopolysaccharidoses (MPS)! 🧬✨ 1️⃣ MPS II & Tividenofusp Alfa (DNL310) Update: After 104 weeks of treatment, patients show remarkable improvement and stabilization, marking a significant milestone in MPS II (Hunter Syndrome) therapy. 🚀💪 The treatment has normalized CSF heparan sulfate and achieved a robust, sustained reduction in neurofilament light chain (NfL), indicating a leap forward in neurodegenerative disease management. 🧠🔬 2️⃣ Launch of DNL126 (ETV:SGSH) for MPS IIIA: Denali kicks off dosing in the Phase 1/2 study of DNL126, targeting MPS IIIA (Sanfilippo Syndrome Type A). Early mouse model studies show promising reductions in heparan sulfate, correlating with cognitive function improvements. 🐁💡 🔍 Why It Matters: Innovation at its Best: Denali’s BBB-crossing enzyme replacement therapies offer new hope, tackling both brain and physical symptoms of MPS diseases. 🌉💊 Community and Science Unite: Collaborative efforts aim for swift approval, bringing new treatment options closer to reality for MPS families. 🤝❤️ 🌈 Looking Ahead: With continued global collaboration and innovative research, Denali is on the fast track to revolutionizing treatment options for MPS diseases, aiming to enhance quality of life for affected individuals and their families. 🌍🙌 Stay tuned for more updates in this transformative journey! 📢 #MPSII #MPSIIIA #TividenofuspAlfa #DNL126 #DenaliTherapeutics #NeurodegenerativeDiseases #InnovativeTherapies #HopeForMPS #ScienceNews #MedicalAdvancements 🌟🔬🧬

A jam-packed Day 1 at World Orphan Drug Congress Europe has come to an end and some really interesting and important topics have been discussed! Lots of conversation about #cellandgenetherapy and questions around durability, how best to communicate #value and manage expectations, and whether existing #paymentmodels actually solve the high price tag issue. Significant focus on the #raredisease #patientvoice and continuing to ensure early input but #innovation is moving rapidly and how #sustainable is this growth. Finally, there's a sentiment that the European market is well-known and #accessopportunities beyond need to be explored and better understood.

The advancements in pharmaceutical science are bringing new therapies, and with them new drug products to market. In this dynamic and competitive landscape, the question arises: what does it take to stand out? In essence, modern therapies require modern CDMOs. I take pride in contributing to the success of one such forward-thinking organization, ten23 health. Discover what makes us different. #pharmaceuticals #CDMO #Innovation #ten23health #pharma #pharmaceuticalmanufacturing #drugproduct #Patients #People #Planet

Deeper Data. Better Outcomes. Focusing on long-term care can significantly benefit underrepresented patients and vulnerable populations by improving access to therapies and coordinating care, leading to better outcomes. Learn more: https://lnkd.in/eRuphcNT #LongTermCare #Biopharmaceuticalnnovation #SilverSurge #LifeSciences

Insufficiency. That's the word that describes the current state of plasma collection in the EU. We rely on life-saving plasma-derived medicines every day, but close to 𝟒𝟎% of the plasma we need comes from the United States. Such high reliance on third-country plasma collection is not a sustainable path on which to continue. The clinical need for plasma-derived medicines (PDMPs) continues to grow globally. These treatments are extending lives, improving quality of life, and reducing complications for patients. 𝐖𝐡𝐚𝐭 𝐜𝐚𝐧 𝐰𝐞 𝐝𝐨? ↳ Evidence-based policies are needed to boost plasma collection in Europe while preserving proven collection methods. ♻️If you found this post insightful, let others know too. #EUNeedsMorePlasma